MDTW (MD Total Wellness) review

MDTW advertises office-based semaglutide and tirzepatide treatment in Brea, California. The same page also sells a retatrutide option described as a research peptide. Those offers should not be treated as interchangeable, and this profile does not recommend enrollment.

FDA’s current guidance states that retatrutide cannot be used in compounding under federal law. It is not a component of an FDA-approved drug and has not been found safe and effective for any condition. A clinic’s research-peptide label does not establish an FDA-approved treatment or participation in an authorized clinical trial.

This is general FDA guidance relevant to the product advertised, not an FDA warning letter addressed to MDTW. The sources reviewed do not establish the clinic’s individual regulatory status or adjudicate its conduct.

The clinic lists semaglutide at $199 for the first month’s starting dose, then $299 monthly; tirzepatide is $299 initially, then $399. It describes those ongoing prices as covering all doses. The program includes medication, monthly MD/PA appointments, in-office lab testing, nutrition guidance and body-composition tracking. Confirm which labs are included and any additional charges before paying.

This model requires assessing the practicalities of office visits, not simply comparing a mail-order subscription price. MDTW names David Oliak, MD, and Allison Mollet, PA-C, as its providers. Their identification on the practice website is not an independent credential or quality verification.

The site describes pay-as-you-go care without a contract and same-day office dispensing when appropriate. It does not identify an assigned compounding pharmacy or establish a refund formula in the reviewed offer. Ask for the exact prescription and dispensing source, and written cancellation terms. Claims about brand-drug trial results do not prove identical outcomes for the compound you would receive.